期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

核苷类似物抗乙肝病毒治疗后耐药新认识 被引量：24

原文传递
导出
摘要 核苷类似物长期抗乙肝病毒（HBV）治疗的选用所面临的最重要问题之一是治疗过程中HBV的耐药性.目前所有口服核苷类似物治疗过程中均可出现耐药性,包括拉米夫定（LAM）、阿德福韦（ADV）、恩替卡韦和替比夫定.然而,对耐药相关的一些问题国内外均没有共识.
作者 侯金林 孙剑
机构地区 南方医科大学南方医院感染内科
出处 《中华传染病杂志》 CAS CSCD 北大核心 2006年第3期145-147,共3页 Chinese Journal of Infectious Diseases
关键词 核苷类似物 治疗后 抗乙肝病毒 乙肝病毒(HBV) 药新 治疗过程 耐药性 拉米夫定 阿德福韦 恩替卡韦
分类号 R512.62 [医药卫生—内科学] R581.1 [医药卫生—内分泌]
  • 相关文献

参考文献7

  • 1Locarnini S,Hatzakis A,Heathcote J,et al.Management of antiviral resistance in patients with chronic hepatitis B.Antivir Ther,2004,9:679-693.
  • 2Chin R,Shaw T,Torresi J,et al.In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-beta D-2,6 diaminopurine dioxolane and 2' fluoro-5-methyl beta-L-arabi nofuranosyluracil.Antimicrob Agents Chemother,2001,45:2495-2501.
  • 3Delaney Ⅳ,Locarnini S,Shaw T.Resistance of hepatitis B vi rus to antiviral drugs:current aspects and directions for future investigation.Antivir Chem Chemother,2001,12:1-35.
  • 4Sun J,Wang Z,Ma S,et al.Clinical and virological characteristics of lamivudine resistance in chronic hepatitis B patients:a single center experience.J Med Virol,2005,75:391-398.
  • 5Yuan MF,Sablon E,Hui CK,et al.Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.Hepatology,2001,34:785-791.
  • 6Lampertico P,Vigano M,Manenti E,et al.Adefovir rapidly suppresses hepatitis B in HBeAg negative patients developing genotypic resistance to lamivudine.Hepatology,2005,42:1414-1419.
  • 7侯金林.恩替卡韦:慢性乙型肝炎治疗的新选择[J].肝脏,2005,10(2):164-166. 被引量：38

二级参考文献18

  • 1Lewin S, Walters T, Locarnini S. Hepatitis B treatment: rational combination chemotherapy based on viral kinetic and animal model studies. Antivir Res,2002,55: 381-396.
  • 2Schneller SW. Carbocylic nucleosides (carbonucleosides) as new therapeutic leads. Curr Top Med Chem,2002:1087-1092.
  • 3Marion PL, Salazar FH, Winters MA, et al. Potent effecacy of entecavir(BMS-200475) in a duck model of hepatitis B virus infection. Antimicrob Agents Chemother, 2002,46:82-88.
  • 4Yamanaka G. Metabolic studies on BMS-200475,a new conpound active against hepatits B virus. Antimicrob Agents Chemother, 1999,43:190-193.
  • 5Levine S. Efficacies of entecavir ngainst lamivudine-resistant hepatitis B virus replication and recombinatant polymerases in vitro. Antimicrob Agents Chemother, 2002,46: 2525-2532.
  • 6Bifano M. Hepatic impairment does not alter single-does pharmacokinetics and safety of entecavir. Hepatology, 2004,40: ( 4 suppl. 1 ): 1149.
  • 7Wolters LM, Hansen BE, Niesters HE, et al. Viral dynamics during and after entecavir therapy in patients with chronic hepatitis B. J Hepatol,2002,37:137-144.
  • 8Chang T. Sustained viral load and ALT reduction following 49 weeks of entecavir treatment in subjects with chronic hepatitis B who have failed lamivudine.Hepatology, 2002,36.
  • 9Schiff ER. Entecavir 1.0 mg is consistently superior to lamivudine at 48 weeks across multiple baseline HBV disease characteristics in lamivudine refractory patients. Hepatology, 2004,40:(4 suppl. 1): 131.
  • 10Chang T. Entecavir is superior to lamivudine for the treatment of HBeAg( + )chronic hepatitis B: results of phase Ⅲ study ETV-022 in nucleoside-naive patients. Hepatology, 2004,40:(4 suppl. 1): 193A.

共引文献37

同被引文献156

引证文献24

二级引证文献96

中华传染病杂志
2006年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部